BioNTech to acquire Novartis GMP manufacturing site in Marburg, Germany

BioNTech signed a share purchase agreement with Novartis to acquire its GMP certified manufacturing facility in Marburg, Germany, to expand COVID-19 vaccine production capacity by up to 750 million doses per year.

“This acquisition reflects BioNTech's commitment to expand its manufacturing capacity to meet the global demand for a potential COVID-19 vaccine.”biontech.com

• 1 source
• biontech.comBioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021Sep 1, 2020

Summarized from public sources; check the original articles before acting on it.